440 completed, 99 recruiting, 74 terminated, 61 unknown. 304 Phase 2, 303 Phase 1, 65 Not applicable, 58 Phase 3, 17 Early Phase 1.
Follow Neuroectodermal Tumors, Primitive, Peripheral: new trials by email Literature Review of Neuroectodermal Tumors, Primitive, Peripheral trials Research Report on Neuroectodermal Tumors, Primitive, Peripheral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-09-01 |
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 2 | Not yet recruiting | New Approaches to Neuroblastoma Therapy Consortium | 118 | 2026-12-31 | 2026-08-21 |
| Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma CIML-NK Cells - Neuroblastoma | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-12-01 | 2026-08-24 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-10-05 |
| Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma Biospecimen Collection, Computed Tomography, Florbenguane F18 - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 2 | Withdrawn | Children's Oncology Group | 2026-09-22 | 2026-09-16 | |
| B7-H3.CD28Z.CART in Solid Tumors B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Pediatric Solid Tumor, Neuroblastoma | Phase 1 | Recruiting | Robbie Majzner | 40 | 2026-08-24 | 2026-09-03 |
| Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma [211At]MABG - Neuroblastoma (NB) | Early Phase 1 | Recruiting | Sichuan University | 10 | 2026-07-21 | 2026-08-21 |
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Dinutuximab Beta, Induction chemotherapy - High Risk Neuroblastoma | Phase 1 | Recruiting | Chang Gung Memorial Hospital | 30 | 2026-07-01 | 2026-10-06 |
| Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Naxitamab - High-Risk Neuroblastoma | Phase 2 | Recruiting | Shaare Zedek Medical Center | 10 | 2026-06-23 | 2026-09-17 |
| A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma 18F-MFBG - Neuroblastoma | Completed | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 43 | 2026-06-01 | 2026-09-22 | |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma Therapeutic Inducers of Natural Killer Killing (ThINKK) - Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid) | Phase 1 | Not yet recruiting | Michel Duval | 12 | 2026-05-01 | 2026-04-08 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. 18F-MFBG PET/CT imaging - Neuroblastoma | Phase 2 | Not yet recruiting | Institut Curie | 30 | 2026-03-01 | 2025-09-03 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells - Rhabdomyosarcoma, Ewing Sarcoma | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 | 2026-08-13 |
| Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide - Neuroblastoma (NB), Neuroblastoma in Children | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 27 | 2026-01-06 | 2026-10-01 |
Showing 20 of 796. Sign in to see all of them.
Neuroblastoma (652) · Sarcoma (173) · Osteosarcoma (141) · Wilms Tumor (121) · Rhabdomyosarcoma (104) · Neoplasms (99) · Medulloblastoma (91) · Sarcoma, Ewing (90) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (81) · Breast Neoplasms (78) · Lymphoma, Non-Hodgkin (78) · Recurrence (78) · Burkitt Lymphoma (74) · Esthesioneuroblastoma, Olfactory (74)
Neoplasms, Glandular and Epithelial (796) · Neoplasms, Nerve Tissue (795) · Neoplasms by Histologic Type (793) · Neoplasms, Neuroepithelial (793) · Neuroectodermal Tumors (792) · Neoplasms, Germ Cell and Embryonal (779) · Neuroectodermal Tumors, Primitive (777) · Neoplasms (697) · Neoplasms by Site (328) · Neoplasms, Connective and Soft Tissue (275) · Nervous System Diseases (209) · Urogenital Diseases (199) · Urogenital Neoplasms (199) · Female Urogenital Diseases (191)
Cyclophosphamide (117) · Etoposide (79) · Filgrastim (65) · Vincristine (65) · Carboplatin (61) · Doxorubicin (59) · Melphalan (51) · Topotecan (51) · Temozolomide (48) · Irinotecan (47) · Radiotherapy (47) · Isotretinoin (45) · Cisplatin (44) · Peripheral Blood Stem Cell Transplantation (40) · Granulocyte Colony-Stimulating Factor (35)
National Cancer Institute (NCI) (96) · Children's Oncology Group (73) · Memorial Sloan Kettering Cancer Center (60) · New Approaches to Neuroblastoma Therapy Consortium (24) · St. Jude Children's Research Hospital (24) · Giselle Sholler (18) · Fred Hutchinson Cancer Center (16) · Children's Cancer and Leukaemia Group (15) · Baylor College of Medicine (14) · Dana-Farber Cancer Institute (13) · City of Hope Medical Center (10) · M.D. Anderson Cancer Center (8) · Vanderbilt-Ingram Cancer Center (8) · Emory University (7) · Institut Curie (7)
United States (573) · Canada (104) · Australia (61) · France (56) · United Kingdom (56) · China (38) · Puerto Rico (38) · Italy (37) · Spain (37) · Germany (36) · Switzerland (32) · Netherlands (25) · New Zealand (23) · Austria (19) · Belgium (19)
Giselle Sholler, MD (14) · Brian Kushner, MD (11) · Brian H. Kushner, MD (8) · Nai-Kong V. Cheung, MD, PhD (8) · Shakeel Modak, MD (8) · Katherine K. Matthay, MD (6) · Kenneth G. Lucas, MD (6) · Frank Berthold, MD (5) · John M. Maris, MD (5) · Steven DuBois, MD (5) · Yizhuo Zhang (5) · Andrew David J. Pearson, MD, FRCP, DCh (4) · Elizabeth Fox, MD (4) · Ruth Ladenstein, MD (4)
PMID 31401903, PMID 23633099, PMID 17369569, PMID 19171714, PMID 19805691, PMID 20567002, PMID 20847174, PMID 20879881, PMID 22682017, PMID 27465021, PMID 34028986, PMID 34435684, PMID 34486544, PMID 37883734, PMID 38917371, PMID 41920422, PMID 10706954, PMID 10797354, PMID 10882162, PMID 11118469, PMID 11464889, PMID 11857322, PMID 11904735, PMID 12091876, PMID 12101494, PMID 12165894, PMID 12218188, PMID 12525530, PMID 12658506, PMID 12880954, PMID 12932669, PMID 14767498, PMID 15033677, PMID 15163307, PMID 15269160, PMID 15337804, PMID 15459300, PMID 1576319, PMID 15814645, PMID 15869455, PMID 15950727, PMID 16129365, PMID 16234526, PMID 16314647, PMID 16382125, PMID 16382236, PMID 1638557, PMID 16421427, PMID 16435380, PMID 1643631
U10CA098543 (32), U10CA180886 (31), P01CA081403 (16), P30CA068485 (10), P30CA008748 (9), P30CA033572 (7), 2023 (6), U01CA097452 (5), UM1CA097452 (5), P30CA043703 (4), UM1CA228823 (4), P30CA006516 (3), P30CA022453 (3), R01CA167632 (3), U01CA069856 (3)